TY - BOOK AU - Stefano Aliberti AU - James D. Chalmers AU - Mathias W. Pletz TI - Anti-infectives and the Lung: ERS Monograph SN - 1849840849 U1 - 616.2/38 ALI PY - 2017/// CY - 442 Glossop Road, Sheffield, S10 2PX, UK PB - European Respiratory Society KW - N1 - Contents: an overview mechanisms and epidemiology dosing therapeutic drug monitoring and continuous infusions Chapter 4 Inhaled antibiotics in chronic airway infections Chapter 5 Inhaled antibiotics in critical care Chapter 6 Identifying patients with pneumonia due to MDR organisms coming from the community Chapter 7 Antibiotic stewardship in the community Chapter 8 Antibiotic stewardship in the hospital setting a tripleedged sword Chapter 13 Treatment options for MDR and XDRTB Chapter 14 Perspectives on antibiotic treatment of NTM pulmonary disease Chapter 15 Antibiotics for pleural infections Chapter 16 Antibiotics in interstitial lung diseases Chapter 17 Insights into antibiotic use in children with CAP New Drugs for Bad Bugs and beyond Chapter 19 Combination antibiotic therapy and synergy in HAP and VAP Chapter 9 Antibiotic in acute exacerbation of asthma and COPD to whom when and how? why what when and to whom? Blank page Other titles in the series N2 - Pulmonary infections are a major cause of morbidity and mortality worldwide. Adequate and timely treatment of these infections is therefore of vital importance, especially when considering the emerging problem of antimicrobial resistance. This Monograph provides a comprehensive up-to-date overview of the use of anti-infectives in lung diseases, with chapters covering community- and hospital-acquired pneumonia, exacerbations of asthma and chronic obstructive pulmonary disease, tuberculosis and nontuberculous mycobacteria pulmonary disease, pleural infections, and fungal diseases. Other chapters address antibiotic stewardship in the community and hospital settings, and the use of antibiotics in specific patient groups (e.g. critically ill and paediatric patients). Mechanisms of action and resistance, diagnostic approaches, therapeutic options (e.g. combination therapy, dosing and routes of administration), and the development of new drugs are also discussed ER -